AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34896356 — intervention group
Group type: COMPARATOR
Intervention: In-person clinical care
Number of subjects: 124
Study 34896459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lattice SBRT delivering 20 Gy in 5 fractions with a simultaneous integrated boost (SIB) of 66.7 Gy.
Number of subjects: 20
Study 34896641 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access to publicly subsidized physiotherapy
Number of subjects: 0
Study 34896641 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard referral to physiotherapy)
Number of subjects: 0
Study 34896646 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode Laser fiber type-selective stimulator (DLss)
Number of subjects: 20
Study 34896646 — intervention group
Group type: COMPARATOR
Intervention: Traditional quantitative sensory testing (QST)
Number of subjects: 20
Study 34897194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 0
Study 34897194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study 34897194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0
Study 34897194 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34897375 — intervention group
Group type: EXPERIMENTAL
Intervention: FATIGUE-PRO instrument (31 items across three scales: physical fatigue, mental and cognitive fatigue, susceptibility to fatigue)
Number of subjects: 106
Study 34897582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg qw
Number of subjects: 391
Study 34898139 — intervention group
Group type: EXPERIMENTAL
Intervention: LentiGlobin infusion
Number of subjects: 35
Study 34898239 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (Dara-KRd)
Number of subjects: 123
Study 34898392 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged continuous monitoring of regional lung function
Number of subjects: 0
Study 34898461 — intervention group
Group type: EXPERIMENTAL
Intervention: DART assessment
Number of subjects: 76
Study 34898461 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist-led triage
Number of subjects: 76
Study 34898461 — intervention group
Group type: EXPERIMENTAL
Intervention: DART user satisfaction
Number of subjects: 76
Study 34898655 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised pacemaker reprogramming
Number of subjects: 100
Study 34898655 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 34899170 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular Vagus Nerve Stimulation (taVNS) during robotic training (9 sessions, 1 hour each, 3 times a week for 3 weeks)
Number of subjects: 36
Study 34899170 — intervention group
Group type: COMPARATOR
Intervention: Robotic training without taVNS (control group)
Number of subjects: 36
Study 34899612 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg/kg biweekly PEG-rhGH
Number of subjects: 585
Study 34899612 — intervention group
Group type: COMPARATOR
Intervention: 0.20 mg/kg once-weekly PEG-rhGH
Number of subjects: 585
Study 34899612 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg/kg daily rhGH
Number of subjects: 585
Study 34899612 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting PEG-rhGH
Number of subjects: 585
Study 34900237 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34900661 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross Tissue Response (GTR) system
Number of subjects: 102
Study 34900737 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34900741 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery + Cs-131
Number of subjects: 49
Study 34901095 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34901100 — intervention group
Group type: EXPERIMENTAL
Intervention: Botanical product containing cistanche and ginkgo extracts
Number of subjects: 0
Study 34901100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34901129 — intervention group
Group type: EXPERIMENTAL
Intervention: Beans-vegetables dietary pattern
Number of subjects: 3334
Study 34901129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-meat-eggs dietary pattern
Number of subjects: 3334
Study 34901129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuts-whole grains dietary pattern
Number of subjects: 3334
Study 34901129 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-poultry-seafood dietary pattern
Number of subjects: 3334
Study 34901129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-wheat-fruits dietary pattern
Number of subjects: 3334
Study 34901220 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training for six months
Number of subjects: 0
Study 34901220 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34901464 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.5% moxifloxacin plus topical placebo plus sham CXL
Number of subjects: 0
Study 34901464 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.5% moxifloxacin plus difluprednate 0.05% plus sham CXL
Number of subjects: 0
Study 34901464 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% moxifloxacin plus difluprednate 0.05% plus CXL
Number of subjects: 0
Study 34901693 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-based anthropometric cutoffs for adolescent girls (10 to <19 y)
Number of subjects: 0
Study 34901797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 4mg weekly for 24 weeks
Number of subjects: 16
Study 34901797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib treatment
Number of subjects: 16
Study 34901863 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0
Study 34901863 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34901885 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (3 μg in 0.5 mL, intramuscular injection) administered on day 0 and day 28
Number of subjects: 942
Study 34901885 — intervention group
Group type: COMPARATOR
Intervention: Control group (seropositive controls and seronegative controls)
Number of subjects: 942
Study 34901915 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy (AIT)
Number of subjects: 46024
Study 34901915 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 46024
Study 34901926 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health coaching intervention for T2DM
Number of subjects: 0
Study 34901926 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34902012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0
Study 34902012 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study 34902047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis originating from the abdomen
Number of subjects: 2019
Study 34902047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis originating from the urinary tract, cardiovascular, and skin infections
Number of subjects: 2019
Study 34902047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis originating from the CNS
Number of subjects: 2019
Study 34902047 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of abdominal and pulmonary infections
Number of subjects: 2019
Study 34902047 — intervention group
Group type: EXPERIMENTAL
Intervention: Source of infection
Number of subjects: 2019
Study 34902265 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg daily for 12 weeks
Number of subjects: 14
Study 34902336 — intervention group
Group type: EXPERIMENTAL
Intervention: USPSTF2013 criteria
Number of subjects: 5819
Study 34902336 — intervention group
Group type: COMPARATOR
Intervention: PLCOm2012 model (risk threshold of at least 1.70% at 6 years)
Number of subjects: 5819
Study 34902506 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2375
Study 34902506 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD
Number of subjects: 2375
Study 34902623 — intervention group
Group type: COMPARATOR
Intervention: Accelerated intermittent Theta Burst Stimulation (aiTBS) targeting the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 41
Study 34902623 — intervention group
Group type: COMPARATOR
Intervention: aiTBS targeting the left DLPFC
Number of subjects: 41
Study 34902760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 0
Study 34902760 — intervention group
Group type: COMPARATOR
Intervention: Cladribine
Number of subjects: 0
Study 34902760 — intervention group
Group type: COMPARATOR
Intervention: Alemtuzumab
Number of subjects: 0
Study 34902760 — intervention group
Group type: COMPARATOR
Intervention: Alemtuzumab and Cladribine
Number of subjects: 0
Study 34902800 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sedation with 10 mg/kg/h Propofol and nasal oxygen 0.3 ml/kg/min
Number of subjects: 25
Study 34902818 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric scores at T0 (outbreak), T1 (lockdown), T2 (reopening)
Number of subjects: 166
Study 34902818 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality disorders (PDs)
Number of subjects: 166
Study 34902818 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia (SKZ)
Number of subjects: 166
Study 34902818 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive-compulsive (OC) symptoms
Number of subjects: 166
Study 34903176 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloids (80% balanced solutions)
Number of subjects: 6314
Study 34903176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative colloids
Number of subjects: 6314
Study 34903176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients undergoing low- or intermediate-risk surgery
Number of subjects: 6314
Study 34903176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients undergoing low- or intermediate-risk surgery
Number of subjects: 6314
Study 34903176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients undergoing high-risk surgery
Number of subjects: 6314
Study 34903176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients undergoing high-risk surgery
Number of subjects: 6314
Study 34903176 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced fluid monitoring strategies
Number of subjects: 6314
Study 34903190 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥4 antenatal care visits
Number of subjects: 21223
Study 34903190 — intervention group
Group type: COMPARATOR
Intervention: <4 antenatal care visits
Number of subjects: 21223
Study 34903218 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 104
Study 34903251 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-enhanced personal construct therapy (PCT-VR)
Number of subjects: 225
Study 34903251 — intervention group
Group type: COMPARATOR
Intervention: Personal construct therapy (PCT)
Number of subjects: 225
Study 34903251 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 225
Study 34903251 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 225
Study 34903452 — intervention group
Group type: EXPERIMENTAL
Intervention: RO4929097 in combination with exemestane
Number of subjects: 15
Study 34903471 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasis-directed radiotherapy (MRT)
Number of subjects: 91
Study 34903471 — intervention group
Group type: COMPARATOR
Intervention: Control (no MRT)
Number of subjects: 91
Study 34903545 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Measure for Post-Acute Care mobility scale
Number of subjects: 211
Study 34903842 — intervention group
Group type: EXPERIMENTAL
Intervention: CAN04 (1.0-10.0 mg/kg weekly)
Number of subjects: 22
Study 34904176 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ILI (requiring only self-reported fever)
Number of subjects: 1040
Study 34904176 — intervention group
Group type: COMPARATOR
Intervention: ILI (WHO definition including fever)
Number of subjects: 1040
Study 34904176 — intervention group
Group type: COMPARATOR
Intervention: ILI definitions (both modified and WHO)
Number of subjects: 1040
Study 34904176 — intervention group
Group type: COMPARATOR
Intervention: ILI
Number of subjects: 1040
Study 34904191 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector classifier incorporating fractional anisotropy and mean diffusivity measured in deep white matter, and age at the time of injury.
Number of subjects: 246
Study 34904191 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector classifier
Number of subjects: 246
Study 34904813 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of poly(ADP-ribose) polymerase
Number of subjects: 0
Study 34904813 — intervention group
Group type: EXPERIMENTAL
Intervention: Other DDR inhibitors
Number of subjects: 0
Study 34904813 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR/CHK1 inhibitors
Number of subjects: 0
Study 34904813 — intervention group
Group type: EXPERIMENTAL
Intervention: ATM/CHK2 inhibitors
Number of subjects: 0
Study 34904813 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-PKcs inhibitors
Number of subjects: 0
Study 34904813 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase θ inhibitors
Number of subjects: 0
Study 34904871 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint deep learning model for T1 contrast-enhancing lesion segmentation
Number of subjects: 796
Study 34904871 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint deep learning model for T1 unenhancing lesion segmentation
Number of subjects: 796
Study 34904871 — intervention group
Group type: COMPARATOR
Intervention: Individual training for T1 contrast-enhancing lesions
Number of subjects: 796
Study 34905051 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (BS)
Number of subjects: 158
Study 34905086 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) via mesenteric injection
Number of subjects: 20
Study 34905086 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) via enteral route
Number of subjects: 20
Study 34905144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin (single-dose 1500 mg IV or two-dose regimen 1000 mg IV on day 1, 500 mg IV on day 8)
Number of subjects: 39
Study 34905749 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids (DAs) used for counseling in the intervention group
Number of subjects: 66
Study 34905749 — intervention group
Group type: COMPARATOR
Intervention: Usual care without a DA in the control group
Number of subjects: 66
Study 34905795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid argon plasma coagulation-assisted endoscopic mucosal resection (hAPC-EMR)
Number of subjects: 40
Study 34906130 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary education program and Tai Chi exercise (Baduanjin), 4-week program with 2-h weekly talks and 1-h Tai Chi class.
Number of subjects: 112
Study 34906201 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFAs
Number of subjects: 400
Study 34906201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 34906208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-guided pre-emptive pharmacogenetic testing to support clinical decision making on antidepressant selection and dosing.
Number of subjects: 0
Study 34906208 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (antidepressant pharmacotherapy selected by the treating physician according to current treatment guidelines without knowledge of PGx test results).
Number of subjects: 0
Study 34906222 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT Skills Training for Emotional Problem Solving for Adolescents (experimental group)
Number of subjects: 20
Study 34906222 — intervention group
Group type: COMPARATOR
Intervention: Control condition (control group)
Number of subjects: 20
Study 34906248 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated local anesthetic solution injected through the catheter with color Doppler ultrasound visualization.
Number of subjects: 83
Study 34906487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 18
Study 34906544 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 205
Study 34906697 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34906976 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with final angiographic expanded Treatment in Cerebral Infarction score of 2c to 3
Number of subjects: 130
Study 34906976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral no-reflow detected by CT/MRI perfusion imaging at 24 hours
Number of subjects: 130
Study 34906983 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual walking in patients with PD
Number of subjects: 206
Study 34906983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task walking in patients with PD
Number of subjects: 206
Study 34906983 — intervention group
Group type: COMPARATOR
Intervention: Usual walking in healthy controls
Number of subjects: 206
Study 34906983 — intervention group
Group type: COMPARATOR
Intervention: Dual-task walking in healthy controls
Number of subjects: 206
Study 34907053 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism diagnostic pathways
Number of subjects: 0
Study 34907053 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial recognition of possible autism; referral and triaging; diagnostic model; providing feedback to parents
Number of subjects: 0
Study 34907053 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in partnership with families; interagency working; training, service evaluation and development
Number of subjects: 0
Study 34907057 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine Video-Feedback Intervention (TVFI)
Number of subjects: 0
Study 34907057 — intervention group
Group type: COMPARATOR
Intervention: Booklet Psychoeducational Intervention
Number of subjects: 0
Study 34907058 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly self-reported illness prevalence
Number of subjects: 471
Study 34907058 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly self-reported illness prevalence by sex
Number of subjects: 471
Study 34907058 — intervention group
Group type: EXPERIMENTAL
Intervention: Time loss due to illness
Number of subjects: 471
Study 34907058 — intervention group
Group type: EXPERIMENTAL
Intervention: Common illness symptoms reported
Number of subjects: 471
Study 34907058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex differences in reported symptoms
Number of subjects: 471
Study 34907058 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness prevalence by season
Number of subjects: 471
Study 34907065 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoma closure with application of a non-absorbable mesh in the sublay position
Number of subjects: 68
Study 34907065 — intervention group
Group type: COMPARATOR
Intervention: Stoma closure without a mesh
Number of subjects: 68
Study 34907170 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (30 μg, 2 doses, 21 days apart)
Number of subjects: 160
Study 34907170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 34907192 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCR4 monoclonal antibody mogamulizumab
Number of subjects: 0
Study 34907216 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based machine learning model
Number of subjects: 197
Study 34907467 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined marker configuration (CMC) model using twelve 1-mm tantalum markers for dynamic radiostereometry analysis (dRSA) at 1-year follow-up.
Number of subjects: 2
Study 34907467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid model combining CMC model and theoretic marker positions from computer-assisted models for static radiostereometry analysis (sRSA).
Number of subjects: 2
Study 34907467 — intervention group
Group type: EXPERIMENTAL
Intervention: Static radiostereometry analysis (sRSA) using all markers in the model.
Number of subjects: 2
Study 34907907 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in free sugars
Number of subjects: 29
Study 34907907 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 29
Study 34907980 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine administered at study entry and at weeks 8 and 24
Number of subjects: 575
Study 34907980 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 575
Study 34908153 — intervention group
Group type: EXPERIMENTAL
Intervention: Child exposure (having regular contact with children under 5 living outside of the subject's household)
Number of subjects: 1006
Study 34908153 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent contact with children under 5 living outside of the subject's household
Number of subjects: 1006
Study 34908153 — intervention group
Group type: EXPERIMENTAL
Intervention: Child exposure
Number of subjects: 1006
Study 34908561 — intervention group
Group type: EXPERIMENTAL
Intervention: New-TKA
Number of subjects: 1881
Study 34908561 — intervention group
Group type: COMPARATOR
Intervention: Existing-TKA
Number of subjects: 1881
Study 34909518 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg daily
Number of subjects: 46
Study 34909518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 34909520 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal visits discussing social determinants of health
Number of subjects: 0
Study 34909528 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive policies
Number of subjects: 0
Study 34909537 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34909566 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 77
Study 34909721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitric oxide-releasing SB206 gel
Number of subjects: 707
Study 34909721 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 707